Aptus Pharma share price
BSE: 544529Pharmaceuticals & BiotechnologySmall Cap
Last close ₹491.50down ₹10.00 (1.99%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹501.50.
52-week range of traded prices to 23 Oct 2026
₹48.10Low, 27 Oct 2025₹510.90High, 23 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹843 Cr2,265th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 21 Oct 2026
- 106.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 21 Oct 2026
- 29.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 21 Oct 2026
- 31.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 21 Oct 2026
- 0.43
- Volume, BSEVolume. Shares traded on the last trading day.
- 18,000
Results
Standalone; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Sep 2026, against the half year beforeFiled 21 Oct
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹49 Crup 51.94%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹5.08 Crup 76.69%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 10.4%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2025Filed 11 Nov | Mar 2026Filed 28 Apr | Sep 2026Filed 21 Oct |
|---|---|---|---|
| Revenue | 14.4 | 32.2 | 48.9 |
| Net profit | 1.7 | 2.9 | 5.1 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 12.1% | 8.9% | 10.4% |
Standalone. The 3 half years from Sep 2025, the first on record. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Marketing and Distribution of finished pahrmaceutical formulations, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, EV/EBITDA: a period of the last twelve months does not state its operating profit. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 96% of 220 trading days since Nov 2025.
LowestHighest
Its median13.2Industry median2.8
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Aptus Pharma in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Bafna PharmaceuticalsBAFNAPH | 1,048 | 134.6 | 10.9 | 92.1 | −3.1% | −5.8% | 8.6% | 4.0% | 0.00% |
 Remus PharmaceuticalsREMUS | 1,038 | 28.1 | 3.0 | 18.5 | +37.6% | – | 12.2% | 13.1% | 0.11% |
 Lincoln PharmaceuticalsLINCOLN | 1,027 | 10.6 | 1.4 | 9.9 | +10.2% | +11.7% | 13.5% | 11.3% | 0.35% |
 Sigachi IndustriesSIGACHI | 959 | 37.8 | 1.8 | 23.2 | −9.6% | – | 4.5% | 4.3% | 0.40% |
 Themis MedicareTHEMISMED | 836 | 20.9 | 2.1 | – | −12.8% | – | 10.0% | −10.5% | 0.55% |
 Shree Ganesh RemediesSGRL | 805 | 52.2 | 4.9 | 26.5 | −8.8% | −29.4% | 10.0% | 10.6% | 0.00% |
 Anuh PharmaANUHPHR | 768 | 17.4 | 2.2 | 11.7 | +9.7% | −4.3% | 13.0% | 15.2% | 1.96% |
 Kilitch Drugs (India)KILITCH | 707 | 23.5 | 2.5 | 21.5 | +14.0% | – | 12.5% | 8.9% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
16 Oct · Board meeting
Meeting on 20 Oct 2026: half yearly results
Sep 2026
17 Sep · Analysts
14 Sep · Meeting
Aptus Pharma share price by year
Each calendar year to 2025.Aptus Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 67.80 | – | 67.94 | 33.20 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 30 Sep 2025.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 510.90 | 510.90 | 491.50 | 491.50 | 494.52 | 18,000 |
| 22 Oct 2026 | 496.00 | 501.50 | 496.00 | 501.50 | 500.96 | 13,600 |
| 21 Oct 2026 | 491.70 | 491.70 | 482.10 | 491.70 | 489.36 | 26,800 |
| 19 Oct 2026 | 482.10 | 482.10 | 482.10 | 482.10 | 482.10 | 11,200 |
| 16 Oct 2026 | 472.65 | 472.65 | 472.65 | 472.65 | 472.65 | 10,800 |
| 15 Oct 2026 | 463.40 | 463.40 | 463.00 | 463.40 | 463.39 | 12,800 |
| 14 Oct 2026 | 454.35 | 455.00 | 454.35 | 454.35 | 454.69 | 25,200 |
| 13 Oct 2026 | 464.45 | 464.55 | 422.00 | 463.60 | 460.77 | 49,200 |
| 12 Oct 2026 | 430.00 | 442.45 | 428.00 | 442.45 | 438.93 | 23,200 |
| 9 Oct 2026 | 403.50 | 421.55 | 395.00 | 421.40 | 413.62 | 30,400 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 12 May 2026 | Bonus | 0.4000 | Holders received 3 bonus shares for every 2 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- Legal name
- Aptus Pharma Limited
- BSE code
- 544529
- ISIN
- INE15XJ01010
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Sep 2025
- Face value
- ₹10
- CIN
- U24230GJ2010PLC061957
- Corporate identity number, the registrar of companies' code for it
In BSE SME IPO